Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epidemiological studies suggest that, even in communities with high infection rates, herd immunity through natural infection may not have been achieved, and these studies raise the possibility that a combination of waning immunity and viral antigenic variation may allow for continued circulation of the virus11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Manaus experienced a strong wave of SARS-CoV-2 infection in April and May of 2020, which might have been expected to provide some level of protection or herd immunity in the exposed population. However, despite a low level of transmission from June to December 2020, a resurgence of infection was observed in early 2021 (refs11,57).”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with the seroepidemiological evidence for ongoing spread of infection in a highly exposed population in Manaus, which suggests that there may be susceptibility to reinfection after 6–8 months11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As the Gamma variant was associated with a surge of infections in a region of Brazil estimated to have achieved a high infection rate, it is suspected of being able to infect and cause illness in persons previously infected with other variants 19,29,30 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Several studies have estimated cumulative infections in select countries at specific points in time.6, 7, 8, 9”
From Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Self-citationFerguson, N. M., Laydon, D. J., Nedjati-Gilani, G. L., Imai, N., Ainslie, K. E. C., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z. M., Cuomo-Dannenburg, G., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/77482 · Cited by 3,281
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Mizumoto, K., Kagaya, K., Zarebski, A., & Chowell, G. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.10.2000180 · Cited by 2,276
Empirical Likelihood and General Estimating Equations
Qin, J., & Lawless, J. (1994) · The Annals of Statistics · doi:10.1214/aos/1176325370 · Cited by 1,715
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
"Herd Immunity": A Rough Guide
Fine, P., Eames, K., & Heymann, D. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir007 · Cited by 1,247
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
ESTIMATING PREVALENCE FROM THE RESULTS OF A SCREENING TEST
ROGAN, W. J., & GLADEN, B. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112510 · Cited by 1,001
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Seasonal coronavirus protective immunity is short-lasting
Edridge, A. W. D., Kaczorowska, J., Hoste, A. C. R., Bakker, M., Klein, M., Loens, K., Jebbink, M. F., Matser, A., Kinsella, C. M., Rueda, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1083-1 · Cited by 767
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
Britton, T., Ball, F., & Trapman, P. (2020) · Science · doi:10.1126/science.abc6810 · Cited by 645
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Evolution and epidemic spread of SARS-CoV-2 in Brazil
Candido, D. S., Claro, I. M., de Jesus, J. G., Souza, W. M., Moreira, F. R. R., Dellicour, S., Mellan, T. A., du Plessis, L., Pereira, R. H. M., Sales, F. C. S., et al. (2020) · Science · doi:10.1126/science.abd2161 · Cited by 573
Self-citationBryan, A., Pepper, G., Wener, M. H., Fink, S. L., Morishima, C., Chaudhary, A., Jerome, K. R., Mathias, P. C., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00941-20 · Cited by 527
Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
de Souza, W. M., Buss, L. F., Candido, D. D. S., Carrera, J.-P., Li, S., Zarebski, A. E., Pereira, R. H. M., Prete, C. A., de Souza-Santos, A. A., Parag, K. V., et al. (2020) · Nature Human Behaviour · doi:10.1038/s41562-020-0928-4 · Cited by 422
Self-citationHallal, P. C., Hartwig, F. P., Horta, B. L., Silveira, M. F., Struchiner, C. J., Vidaletti, L. P., Neumann, N. A., Pellanda, L. C., Dellagostin, O. A., Burattini, M. N., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30387-9 · Cited by 398
Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
Uyoga, S., Adetifa, I. M. O., Karanja, H. K., Nyagwange, J., Tuju, J., Wanjiku, P., Aman, R., Mwangangi, M., Amoth, P., Kasera, K., et al. (2021) · Science · doi:10.1126/science.abe1916 · Cited by 328
Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J., Clearly, S., Furrie, E., Greig, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa659 · Cited by 308
Lumley, S. F., Wei, J., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab004 · Cited by 288
Crowding and the shape of COVID-19 epidemics
Rader, B., Scarpino, S. V., Nande, A., Hill, A. L., Adlam, B., Reiner, R. C., Pigott, D. M., Gutierrez, B., Zarebski, A. E., Shrestha, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1104-0 · Cited by 274
Self-citationGenerality of the Final Size Formula for an Epidemic of a Newly Invading Infectious Disease
Ma, J., & Earn, D. J. D. (2006) · Bulletin of Mathematical Biology · doi:10.1007/s11538-005-9047-7 · Cited by 263
Unraveling R0: Considerations for Public Health Applications
Ridenhour, B., Kowalik, J. M., & Shay, D. K. (2014) · American Journal of Public Health · doi:10.2105/ajph.2013.301704 · Cited by 206
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
Ng, D. L., Goldgof, G. M., Shy, B. R., Levine, A. G., Balcerek, J., Bapat, S. P., Prostko, J., Rodgers, M., Coller, K., Pearce, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18468-8 · Cited by 185
Self-citationExplosão da mortalidade no epicentro amazônico da epidemia de COVID-19
Orellana, J. D. Y., da Cunha, G. M., Marrero, L., Horta, B. L., & Leite, I. D. C. (2020) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00120020 · Cited by 162
Will SARS-CoV-2 become endemic?
Shaman, J. L., & Galanti, M. (2020) · Science · doi:10.1126/science.abe5960 · Cited by 161
Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India
Malani, A., Shah, D., Kang, G., Lobo, G. N., Shastri, J. S., Mohanan, M., Jain, R. K., Agrawal, S. R., Juneja, S., Imad, S., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30467-8 · Cited by 151
Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors
Erikstrup, C., Hother, C., Pedersen, O. B., Mølbak, K., Skov, R. L., Holm, D. K., Sækmose, S. G., Nilsson, A. C., Brooks, P. T., Boldsen, J. K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa849 · Cited by 148
Estimating Prevalence Using an Imperfect Test
Diggle, P. J. (2011) · Epidemiology Research International · doi:10.1155/2011/608719 · Cited by 123
Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemicsPreprint
Aguas, R. J., Gonçalves, G., Ferreira, M. U., & Gomes, M. G. M. (2020) · medRxiv · doi:10.1101/2020.07.23.20160762 · Cited by 106
Thompson, C., Grayson, N. E., Paton, R. S., Bolton, J. S., Lourenço, J., Penman, B. S., Lee, L. N., Odon, V., Mongkolsapaya, J., Chinnakannan, S. K., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.42.2000685 · Cited by 98
Importation and early local transmission of COVID-19 in Brazil, 2020
de Jesus, J. G., Sacchi, C. T., Cândido, D. D. S., Claro, I. M., Sales, F. C. D. S., Manuli, E. R., da Silva, D. B. B., de Paiva, T. M., Pinho, M. A. B., Santos, K. C. D. O., et al. (2020) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202062030 · Cited by 97
Self-citationParag, K. V. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009347 · Cited by 88
Self-citationReport 34: COVID-19 infection fatality ratio: estimates from seroprevalence
Brazeau, N., Verity, R., Jenks, S. J., Fu, H. J., Whittaker, C., Winskill, P., Dorigatti, I., Walker, P. G. T., Riley, S., Schnekenberg, R. P., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/83545 · Cited by 86
Self-citationHallal, P. C., Hartwig, F. P., Horta, B. L., Victora, G. D., da Silveira, M. F., Struchiner, C. J., Vidaletti, L. P., Neumann, N. A., Pellanda, L. C., Dellagostin, O. A., et al. (2020) · medRxiv · doi:10.1101/2020.05.30.20117531 · Cited by 86
Lewis, F. I., & Torgerson, P. R. (2012) · Emerging Themes in Epidemiology · doi:10.1186/1742-7622-9-9 · Cited by 82
Have deaths from COVID-19 in Europe plateaued due to herd immunity?
Okell, L., Verity, R., Watson, O. J., Mishra, S., Walker, P. G. T., Whittaker, C., Katzourakis, A., Donnelly, C. A., Riley, S., Ghani, A. C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31357-x · Cited by 77
Self-citationLumley, S., Wei, J., O’Donnell, D., et al. (2020) · medRxiv · doi:10.1101/2020.11.02.20224824 · Cited by 61
Using information theory to optimise epidemic models for real-time prediction and estimation
Parag, K. V., & Donnelly, C. A. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007990 · Cited by 50
Self-citationCrowding and the epidemic intensity of COVID-19 transmissionPreprint
Rader, B. M., Nande, A., Adlam, B., Hill, A. L., Reiner, R. C., Pigott, D. M., Gutiérrez, B., COVID-19 data working group, Brownstein, J. S., Castro, M. C., et al. (2020) · medRxiv · doi:10.1101/2020.04.15.20064980 · Cited by 39
Self-citationStringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections
Eyre, D. W., Lumley, S., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05878-2 · Cited by 35
Tess, B. H., Granato, C. F. H., Alves, M. C. G. P., Pintão, M. C. T., Rizzatti, E. G., Nunes, M. C., & Reinach, F. C. (2020) · medRxiv · doi:10.1101/2020.06.29.20142331 · Cited by 25
Sensitivity of the Wondfo One Step COVID-19 test using serum samples
dos Santos, V. A., Rafael, M. M., Sabino, É. C., & Duarte, A. J. D. S. (2020) · Clinics · doi:10.6061/clinics/2020/e2013 · Cited by 22
Parag, K. V. (2020) · medRxiv · doi:10.1101/2020.09.14.20194589 · Cited by 19
Self-citationKinetics and performance of the Abbott architect SARS-CoV-2 IgG antibody assay
Hamilton, F., Muir, P., Attwood, M., Vipond, A. N. B., Vipond, B., Hopes, R., Moran, E., Maskell, N. A., Warwick, D., Albur, M., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.07.031 · Cited by 16
Eyre, D. W., Lumley, S., O’Donnell, D., et al. (2020) · medRxiv · doi:10.1101/2020.07.21.20159038 · Cited by 14
Optimising Renewal Models for Real-Time Epidemic Prediction and EstimationPreprint
Parag, K. V., & Donnelly, C. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/835181 · Cited by 6
Self-citationCoronavirus prevalence in Brazilian Amazon and Sao Paulo city
Salomon, T., Pybus, O. G., França, R., Castro, M. C., Sabino, E. C., Dye, C., Busch, M., Kraemer, M. U. G., Whittaker, C., Santos, A. A. D. S., et al. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5061/dryad.c59zw3r5n · Cited by 1
Self-citation
Research works printed but not linked: 1
- 10.1186/1742-7622-9-9 · DOI
Cited by
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
“In practice we only consider symmetric cross-immunity βs = β, which is given the prior: β~Beta(2,1)”
BackgroundMethodInfluentialSelf-citationAge-specific mortality and immunity patterns of SARS-CoV-2
O’Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A., Cauchemez, S., & Salje, H. (2021) · Nature · doi:10.1038/s41586-020-2918-0 · Cited by 1,210
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., & Meyerowitz-Katz, G. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00698-1 · Cited by 844
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Crispim, M. A. E., Fraiji, N. A., Pereira, R. H. M., Parag, K. V., da Silva Peixoto, P., Kraemer, M. U. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00183-5 · Cited by 758
Self-citation
Metadata
- Authors
- Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., Crispim, M. A. E., Ferreira, S. C., Fraiji, N. A., Gurzenda, S., Whittaker, C., Kamaura, L. T., Takecian, P. L., da Silva Peixoto, P., Oikawa, M. K., Nishiya, A. S., Rocha, V., Salles, N. A., de Souza Santos, A. A., da Silva, M. A., Custer, B., Parag, K. V., Barral-Netto, M., Kraemer, M. U. G., Pereira, R. H. M., Pybus, O. G., Busch, M. P., Castro, M. C., Dye, C., Nascimento, V. H., Faria, N. R., & Sabino, E. C.
- Affiliations
- Universidade de São Paulo (BR)
- Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (BR)
- Faculdade de Ciências Médicas de Minas Gerais (BR)
- Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil.
- Department of Virology and Experimental Therapy, Institute Aggeu Magalhaes, Oswaldo Cruz Foundation, Recife, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
- Harvard University (US)
- Imperial College London (GB)
- Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
- Center of Mathematics, Computing and Cognition–Universidade Federal do ABC, São Paulo, Brazil.
- Fundação Pró-Sangue Hemocentro de São Paulo (BR)
- Oxford School of Global and Area Studies, Latin American Centre, University of Oxford, Oxford, UK.
- University of California, San Francisco (US)
- Instituto Gonçalo Moniz–Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
- University of Oxford (GB)
- Institute of Applied Economic Research (BR)
- Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Corresponding author
- Buss, Lewis F.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- Faria, Nuno R.
- ORCID
- Buss, Lewis F.
- Prete, Carlos A.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- de Almeida-Neto, Cesar
- França, Rafael F. O.
- Belotti, Maria C.
- Carvalho, Maria P. S. S.
- Costa, Allyson G.
- Crispim, Myuki A. E.
- Ferreira, Suzete C.
- Fraiji, Nelson A.
- Gurzenda, Susie
- Whittaker, Charles
- Kamaura, Leonardo T.
- Takecian, Pedro L.
- da Silva Peixoto, Pedro
- Oikawa, Marcio K.
- Nishiya, Anna S.
- Rocha, Vanderson
- Salles, Nanci A.
- de Souza Santos, Andreza Aruska
- da Silva, Martirene A.
- Custer, Brian
- Parag, Kris V.
- Barral-Netto, Manoel
- Kraemer, Moritz U. G.
- Pereira, Rafael H. M.
- Pybus, Oliver G.
- Busch, Michael P.
- Castro, Márcia C.
- Dye, Christopher
- Nascimento, Vítor H.
- Faria, Nuno R.
- Sabino, Ester C.
- Venue
- Science
- Published
- 2021-01-15
- Volume
- 371
- Issue
- 6526
- Pages
- 288-292
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7857406
- OpenAlex
- W3112547455
- Cited by
- 488
- References
- 47
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 29 · 2023: 56 · 2022: 119 · 2021: 240
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MR/S0195/1)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (18/14389-0)
- Itau Unibanco Todos pela Saude
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, attack rate, seroprevalence, immunoglobulin G antibodies, Manaus, Amazonas, antibody waning, blood donors, epidemic size estimation
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Antibodies, Viral, Blood Donors, Brazil, Female, Humans, Immunoglobulin G, Male, Middle Aged, Seroepidemiologic Studies, Young Adult, Epidemics, Epidemiological Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.